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Abstract
Background and Objectives—Recurrence in lymph node-negative (pN0) colorectal cancer
suggests the presence of undetected occult metastases. Occult tumor burden in nodes estimated by
GUCY2C RT-qPCR predicts risk of disease recurrence. This study explored the impact of the
number of nodes analyzed by RT-qPCR (analytic) on the prognostic utility of occult tumor
burden.
Methods—Lymph nodes (range: 2–159) from 282 prospectively enrolled pN0 colorectal cancer
patients, followed for a median of 24 months (range: 2–63), were analyzed by GUCY2C RT-
qPCR. Prognostic risk categorization defined using occult tumor burden was the primary outcome
measure. Association of prognostic variables and risk category were defined by multivariable
polytomous and semi-parametric polytomous logistic regression.
Results—Occult tumor burden stratified this pN0 cohort into categories of low (60%; recurrence
rate (RR)=2.3% [95% CI 0.1–4.5%]), intermediate (31%; RR=33.3% [23.7%–44.1%]), and high
(9%; RR=68.0% [46.5%–85.1%], p<0.001) risk of recurrence. Beyond race and T stage, the
number of analytic nodes was an independent marker of risk category (p<0.001). When >12 nodes
were analyzed, occult tumor burden almost completely resolved prognostic risk classification of
pN0 patients.
Conclusions—The prognostic utility of occult tumor burden assessed by GUCY2C RT-qPCR is
dependent on the number of analytic lymph nodes.
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Introduction
Lymph node metastases are one of the most important prognostic factors determining
disease recurrence and disease-related mortality in colorectal cancer [1,2]. Although
theoretically rendered cancer free by surgery, patients with nodes devoid of histopathologic
evidence of cancer (pN0) suffer recurrence rates of ~30%, while those rates exceed 50% in
patients with ≥4 lymph nodes harboring macroscopic metastases (pN2) [1–4]. Adjuvant
chemotherapy improves disease-free and overall survival in patients with histopathologically
evident lymph node metastases, but its role in pN0 patients remains unclear [1–6].
Disease recurrence in a substantial fraction of node-negative colorectal cancer patients
suggests the presence of occult metastases that escape conventional detection methods [7–
11]. Conversely, patients who are free of lymph node metastases by any detection method
may have a better prognosis [7–11]. More accurate assessment of occult metastases would
improve clinical risk stratification. In addition, some patients with occult metastases might
benefit from the increasingly effective adjuvant chemotherapy available for colorectal
cancer.
The tumor suppressor GUCY2C (guanylyl cyclase C) is the receptor for the paracrine
hormones guanylin and uroguanylin, gene products universally lost early in intestinal
neoplasia [12,13]. Loss of hormone expression silences GUCY2C signaling which
contributes to malignant transformation by promoting proliferation, crypt hypertrophy,
metabolic remodeling and genomic instability [13]. Highly selective expression by normal
intestinal epithelial cells, and universal over-expression by intestinal tumor cells [14–16],
suggested that GUCY2C might be a specific molecular marker for metastatic colorectal
cancer [11,17,18]. A recent prospective analysis revealed that pN0 colorectal cancer patients
whose nodes expressed GUCY2C mRNA suffered recurrence more frequently than those
with GUCY2C-negative nodes [11], an observation that has been independently validated
[19–21]. Moreover, quantifying molecular tumor burden across the regional lymph node
network dramatically improved the classification of recurrence risk in pN0 patients [18].
There is an established relationship between the number of nodes analyzed by
histopathology and the accuracy of staging in colorectal cancer [1,2,22,23]. While molecular
approaches to identifying occult tumor cells are emerging, the relationship between the
number of nodes analyzed and the accuracy of molecular staging has not yet been explored.
In that context, the accuracy of estimating occult tumor burden across the regional lymph
node network theoretically depends on the number of nodes assessed [18,24]. The present
analysis identifies the relationship between the number of nodes analyzed by GUCY2C RT-
qPCR (analytic nodes) and the accuracy of risk stratification by occult tumor burden in pN0
colorectal cancer patients.
Methods and Materials
Study Design [11,18]
This prospective observational trial at nine centers in the U.S. and Canada explored the
prognostic utility of GUCY2C RT-qPCR in lymph nodes of pN0 colorectal cancer patients.
Investigators and clinical personnel were blinded to results of molecular analyses while
laboratory personnel and analysts were blinded to patient and clinical information. To have
at least 80% power to detect a hazard ratio of 1.6 (P≤0.05, 2-sided) employing categorical
assessment of occult tumor metastases in the original study, 225 pN0 patients were required.
The protocol was approved by the Institutional Review Board of each participating hospital.
The 299 pN0 patients who met eligibility criteria provided 7,310 lymph nodes (range 2–159,
median 21 lymph nodes/patient) for histopathologic examination, of which 2,774 nodes
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(range 1–87, median 8 lymph nodes/patient) were obtained by fresh dissection and eligible
for analysis by RT-qPCR. Disease status obtained in routine follow-up by treating
physicians, including local and distant recurrences, was provided for all patients through
December 31, 2009.
Patients and Tissues [11,18]
Between March 2002 and June 2007, we enrolled 299 stage 0-II pN0 colorectal cancer
patients who provided written informed consent before surgery at one of 7 academic medical
centers and 2 community hospitals in the U.S. and Canada. Patients were ineligible if they
had a previous history of cancer, metachronous extra-intestinal cancer, or perioperative
mortality associated with primary resection. For all eligible patients, preoperative and
perioperative examinations revealed no evidence of metastatic disease. Lymph nodes, and
when available tumor specimens (51%), were dissected from colon and rectum resections
and frozen at −80°C within one hour to minimize warm ischemia. Half of each resected
lymph node was fixed with formalin and embedded in paraffin for histopathological
examination. Lymph node specimens were subjected to molecular analysis if (1) tumor
samples, where available, expressed GUCY2C mRNA above background levels in disease-
free lymph nodes (>30 copies) and (2) at least one lymph node was provided which yielded
RNA of sufficient integrity for analysis. Thus, analysis of the 2,774 lymph nodes available
for molecular analysis from 299 patients revealed that 236 nodes from 76 patients yielded
RNA of insufficient integrity by β-actin RT-qPCR. Elimination of these nodes from analysis
resulted in the exclusion of two patients. Moreover, GUCY2C expression in tumors was
below background levels in 6 patients who also were excluded from further analysis. Of the
resulting 291 eligible patients, 23 were identified by their medical record as black, 259 as
white (Table I), and 9 were of another race or their race could not be identified. These
analyses focus on the 282 patients with known race.
RNA Isolation
RNA was extracted from tissues by a modification of the acid guanidinium thiocyanate-
phenol-chloroform extraction method [15,17]. Briefly, individual tissues were pulverized in
1.0 mL Tri-Reagent (Molecular Research Center, Cincinnati, OH) with 12–14 sterile 2.5
mm zirconium beads in a bead mill (Biospec, Bartlesville, OK) for 1–2 min. Phase
separation was performed with 0.1 mL bichloropropane, and the aqueous phase re-extracted
with 0.5 mL chloroform. RNA was precipitated with 50% isopropanol and washed with 70%
ethanol. Air-dried RNA was dissolved in water, concentration determined by
spectrophotometry, and stored at −80°C.
RT-qPCR
GUCY2C mRNA was quantified by RT-PCR employing an established analytically
validated assay [16]. The EZ RT-PCR kit (Applied Biosystems, Foster City, CA) was
employed to amplify GUCY2C mRNA from total RNA in a 50 μL reaction. Optical strip-
tubes were used for all reactions, which were conducted in an ABI 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA). In addition to the kit components [50 mM
Bicine (pH 8.2), 115 mM KOAc, 10 μM EDTA, 60 nM ROX, 8% glycerol, 3 mM
Mg(OAc)2, 300 μM each dATP, dCTP, and dGTP, 600 μM dUTP, 0.5 U uracil N-
glycosylase, and 5 U rTth DNA polymerase], the reaction master mix contained 900 nM
each of forward (ATTCTAGTGGATCTTTTCAATGACCA) and reverse primers
(CGTCAGAACAAGGACATTTTTCAT), 200 nM Taqman probe (FAM-
TACTTGGAGGACAATGTCACAGCCCCTG-TAMRA), and 1 μg RNA template. The
reference gene β-actin was amplified employing similar conditions except that forward
(CCACACTGTGCCCATCTACG) and reverse
(AGGATCTTCATGAGGTAGTCAGTCAG) primers were 300 nM each, while the Taqman
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probe (FAM-ATGCCC-X(TAMRA)-CCCCCATGCCATCCTGCGTp) was 200 nM. The
thermocycler program employed for RT included: 50° × 2 min, 60° × 30 min, 95° × 5 min;
and for PCR: 45 cycles of 94° × 20 sec, 62° × 1 min. Reactions were performed at least in
duplicate and results averaged.
Statistical Methods
Statistical methods for estimating GUCY2C and β-actin mRNA by logistic regression
analysis were described previously [11,18]. The primary endpoint was molecular risk
category (low, intermediate, high) which was previously defined based on time to recurrence
and recursive partitioning analysis [18]. Time to recurrence for those analyses was defined
as the time from diagnosis to time of last follow-up, local or distant recurrence event, or
death [11,25]. Analyses of molecular risk category by polytomous logistic regression
included an established standard cut-off for the number of lymph nodes harvested for
histopathology and the number of analytic lymph nodes available for molecular (RT-qPCR)
evaluation [18,24]. Models were compared based on the Akaike Information Criteria
(AIC=2k-2ln(L)), where k is the number of parameters and L is the maximized value of the
Likelihood of the estimated model), an established metric for the comparison of non-nested
models [26]. Multivariable model analyses were then completed using semi-parametric
polytomous logistic regression [27,28] to define the relationship between risk level and
number of analytic lymph nodes, using a smooth function for the relationship to analytic
nodes [18], while controlling for other established factors [24]. Inference for this modeling
approach is not incorporated in the software and properties are as yet undetermined. Thus,
5,000 bootstrap samples were utilized to compute confidence intervals and empirical p
values based on the nonparametric bootstrap. The purpose of these multivariable analyses
was to determine the potential impact of the number of analytic nodes available on patient
risk stratification. The association of harvested lymph nodes to analytic lymph nodes was
completed using Spearman's correlation, and visually plotted with a loess smoother.
Confidence intervals for raw survival rates were computed by the exact method of Clopper-
Pearson [29]. All tests were two-sided, and p<0.05 was considered statistically significant.
All analyses were performed with R v 2.11.2, SAS v 9.2.
Results
Patient Characteristics
The 282 pN0 patients had a mean age of 68 years (26–90 years) at diagnosis and 56% were
male (Table I). Clinicopathologic features, including depth of tumor penetration (T1/2, T3,
T4), and tumor anatomical location (right, left, rectal) were similar to national experience
[1–4]. Patients with colon cancer represented 86%, while those with rectal tumors comprised
14%. Black patients comprised 8.2% of the total population enrolled, nearly identical to the
national average for disease-specific racial distribution [30–32]. In this cohort, 59 (21%)
patients provided ≤12 harvested lymph nodes and 223 (79%) patients >12 harvested lymph
nodes for histopathology (Table I), a staging quality standard [1–3]. There were no
significant differences in clinicopathologic characteristics between patients providing
different numbers of lymph nodes for histopathology (Table II).
Occult Tumor Burden and Risk Stratification
Clinical outcomes in pN0 colorectal cancer patients were analyzed by recursive partitioning
using metrics of occult tumor burden estimated by GUCY2C RT-qPCR [18]. Based on time
to recurrence, GUCY2C RT-qPCR stratified pN0 patients into categories in which 170
(60%) patients exhibited low (MolLow), 88 (31%) exhibited intermediate (MolInt), and 24
(9%) exhibited high (MolHigh) (p<0.001) risk of disease recurrence (Fig. 1). All but 4 of the
MolLow patients remained free of disease during follow-up (recurrence rate (RR)=2.3%
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[95% CI 0.1–4.5%]); 29 MolInt patients developed recurrent disease (RR=33.3% [23.7%–
44.1%]); and 16 (RR=68.0% [46.5%–85.1%]) MolHigh patients developed recurrent disease
(p<0.001; Fig. 1). Univariate analysis revealed the expected relationship between advanced
T stage and occult tumor burden (p=0.008; Table I) [18,24]. Similarly, black patients
harbored a greater burden of occult metastatic tumor across their lymph node network,
associated with greater risk, compared to white patients (p=0.007; Table I) [24].
Occult Tumor Burden and Lymph Node Collections
The accuracy of molecular staging depended on the number of lymph nodes harvested for
histopathologic analysis (Table I). Patients with ≤12 harvested lymph nodes exhibited occult
tumor burden that stratified patients in low and intermediate risk categories, with no patients
in the highest risk category (Table I). Conversely, analysis of >12 harvested lymph nodes
reduced the number of patients with intermediate risk while revealing patients with the
highest risk (p=0.002; Table I). This association of staging accuracy by RT-qPCR with
increased lymph nodes harvested for histopathology is reminiscent of established
improvements in histopathologic staging by increased nodal collections [1,2,22,23].
The 282 eligible pN0 patients provided 6,699 lymph nodes (range 2–159, median 21 lymph
nodes/patient) for histopathologic examination, of which 2,570 (range 1–33, median 8
lymph nodes/patient) were analyzed by RT-qPCR. The greater number of lymph nodes
available for histopathology (harvested), compared to molecular analysis (analytic), from
pN0 patients includes those collected after formalin fixation or nodes <5 mm in diameter,
smaller than the limit of bisection [11]. The relationship between accuracy of staging by
occult tumor burden and number of nodes collected for histopathology suggested a direct
association between total nodes harvested (6,699 lymph nodes) and nodes analyzed by RT-
qPCR (2,570 lymph nodes; R=0.49, p<0.001; Fig. 2A). Moreover, molecular risk level
depended on the number of lymph nodes analyzed per patient by RT-qPCR (p<0.001). Thus,
patients providing ≤12 analytic nodes assessed by RT-qPCR exhibited occult tumor burden
that stratified patients in low and intermediate risk categories, with only 3% of patients in
the highest risk category (Fig. 2B). Conversely, >12 analytic nodes assessed by RT-qPCR
improved prognostic resolution, minimizing the number of patients in the intermediate risk
category while maximizing the identification of patients with the lowest and highest risk
(Fig. 2B). Indeed, the polytomous model based on the number of analytic nodes
(AIC=428.45) was preferred in predicting association with risk category compared to the
polytomous model based on the number of nodes harvested for histopathology
(AIC=480.37).
Occult Tumor Burden is an Independent Prognostic Variable Defined by Number of
Analytic Lymph Nodes
Multivariable analyses employing semi-parametric polytomous logistic regression
confirmed that race, T stage, and number of analytic nodes assessed by RT-qPCR are
independently associated with quantification of occult tumor burden and stratification into
risk categories (Table III). This model used analytic nodes as a continuous variable with a
smooth function of unspecified form. Black patients were more likely to be categorized as
high risk on the basis of occult tumor burden compared to white patients (adjusted odds ratio
4.05 [1.01–16.67] p=0.03). Similarly, patients with T3 tumors were more likely to be
categorized as high risk (adjusted odds ratio 5.51 [2.15–31.10]; p<0.001) compared to
patients with T1/T2 tumors. Importantly, the number of analytic nodes analyzed by RT-
qPCR was essential to accurately stratify risk by occult tumor burden (p<0.001; Table III).
Quantification of occult tumor burden using >12 analytic nodes categorized ~70% of pN0
patients with low risk and ~30% of patients with intermediate and high risk (Fig. 3).
Moreover, using ≤25 analytic nodes, which maximizes quantitative information for occult
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tumor burden analysis, completely resolved these latter categories, stratifying all patients
who were not low risk as high risk, eliminating the intermediate risk category (Fig. 3). In
that context, number of analytic lymph nodes assessed by RT-qPCR was an independent
predictor of risk classification by occult tumor burden analysis (p<0.001, Table III).
Discussion
Lymph node metastases are one of the most important prognostic factors in patients with
colorectal cancer [1–3]. In contrast, pN0 patients with lymph nodes ostensibly free of
metastatic disease by histopathology have a recurrence rate approaching ~30% [1–3].
Recurrence in these patients suggests the presence of occult metastases that escape detection
at the time of resection [8,10]. Under-staging by histopathology likely reflects sampling
error [33], and the relative insensitivity of histopathology, which reliably detects only 1
cancer cell in 200 normal cells [34].
Molecular staging overcomes limitations in conventional detection of lymph node
metastases by incorporating all available tissue into analyses, and improving detection
sensitivity through quantifiable, highly sensitive, disease-specific molecular markers
[8,10,35]. Previously, we demonstrated that categorical (yes/no) detection of occult
metastases in regional lymph nodes using GUCY2C RT-PCR was an independent
prognostic marker of recurrence risk in pN0 colorectal cancer patients [11]. Surprisingly,
these studies revealed that ~87% of pN0 colorectal cancer patients harbored occult
metastases in lymph nodes [11]. Occult nodal metastases were associated with an increased
prognostic risk of recurrent disease [11].
These observations reveal an unanticipated diagnostic challenge inherent in the application
of sensitive molecular techniques to lymph node staging, in which clinically insignificant
metastases are detected in most patients [35]. Occult metastases were associated with
increased prognostic risk, but most patients with involved lymph nodes did not progress to
disease recurrence [11]. These considerations suggest a quantitative threshold of occult
tumor metastases above which the prognostic risk for developing recurrent disease increases
[18]. In that context, the prognostic utility of this paradigm was enhanced by quantifying
molecular tumor burden (how much) across the regional lymph node network [18].
Quantification of occult tumor burden by GUCY2C RT-qPCR stratified pN0 patients into a
low risk cohort representing ~60% of the population, with a very low (<5%) incidence of
disease recurrence; an intermediate risk cohort with an incidence of disease recurrence of
~33% and a high risk cohort with >60% incidence of recurrence. Multivariable analyses
revealed that occult tumor burden was a powerful independent prognostic marker of time to
recurrence and disease-free survival [18].
While quantification of occult tumor burden offers a previously unavailable opportunity to
identify patients at risk in the prognostically heterogeneous pN0 population, this staging
paradigm classifies ~30% of patients as having intermediate risk [18]. Intermediate risk
could reflect variations in tumor biology which influence recurrence beyond the quantity of
occult tumor burden in lymph nodes [36,37]. Alternatively, systematic misclassification of
high or low risk patients into the intermediate risk category could result from inaccurate
quantification of occult tumor burden in inadequate collections of analytic lymph nodes.
There is a well-established relationship between the accuracy of conventional staging and
the number of lymph nodes analyzed by histopathology [1,2,22,23]. Collection of greater
numbers of lymph nodes improves the likelihood of identifying macroscopic tumor deposits
by histopathology, which depends on limited tissue sampling techniques [33]. In the context
of molecular paradigms employing GUCY2C RT-qPCR, increased analytic lymph node
collections improve the accuracy of occult tumor burden quantification across the regional
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lymph node network. This is underscored by the observation that quantification of occult
tumor burden employing very small numbers of analytic lymph nodes only identifies
patients with low or intermediate risk, but fails to identify patients with high risk (Fig. 3). In
contrast, analyzing ≥25 lymph nodes eliminates the intermediate risk category, classifying
patients in low or high risk groups (Fig. 3).
Current practice guidelines recommend the collection of ≥12 lymph nodes to optimize
staging of colorectal cancer patients by conventional approaches [1,2]. In contrast, the
present results suggest that analyzing ≥25 lymph nodes for occult tumor burden provides
complete resolution of risk classification in the pN0 population. This approach identified
~70% of patients with near-zero risk, while ~30% of patients were classified with high risk.
This recapitulates the actual risk of this population, in which ~70% of pN0 patients remain
disease-free while up to ~30% of patients ultimately develop recurrent disease (e.g., see Fig.
1) [1–3]. It is noteworthy that this level of accuracy, with complete resolution of risk
stratification, has not been achieved previously for pN0 colorectal cancer patients by any
technique.
While analysis of ≥25 lymph nodes provides the most accurate classification of risk, the data
suggest that patient management can be optimized using >12 lymph nodes. Analysis of >12
lymph nodes provides optimum resolution of patients with low risk and those who do not
have low risk (see Fig. 3). Adding more lymph nodes to the analysis only improves the
accuracy of classifying patients with high risk who were otherwise misclassified as having
intermediate risk, without further improving the classification of low risk patients (see Fig.
3). The utility of >12 lymph nodes to optimally classify patients with low risk and those who
do not have low risk (consequently, high risk) by occult tumor burden analysis suggests that
this emerging molecular paradigm is compatible with current recommendations guiding
lymph node collection [1,2].
The present observations demonstrate that the accuracy of staging pN0 colorectal cancer
patients by occult tumor burden analysis employing GUCY2C RT-qPCR is critically
dependent on the number of analytic lymph nodes. They suggest that with >12 lymph nodes
for the analysis, occult tumor burden can provide near complete resolution of prognostic risk
stratification in the otherwise heterogeneous pN0 cohort. These studies suggest a very close
relationship between the quantity of tumor deposits in regional lymph nodes and the risk of
metastatic disease. They underscore the importance of lymphatic spread of colorectal cancer
as an essential process in tumor dissemination and metastatic disease [38]. Conversely, these
observations challenge the presumed significance of hematogenous spread and circulating
tumor cells as key elements underlying disease progression [38]. Further, they call into
question the utility of genomic signatures, expression profiling, and other multi-component
“omic” analyses of primary tumors, which to date have been only modestly useful in
stratifying pN0 risk [36,37]. Most importantly, the ability of occult tumor burden analysis to
resolve prognostic risk offers an unprecedented opportunity to identify patients who could
most benefit from adjuvant treatment in the otherwise therapeutically ambiguous pN0
population [1–3,5,6].
Conclusion
There is emerging recognition of the utility of occult tumor burden in regional lymph nodes,
quantified by molecular techniques, for staging to assess the prognostic risk of colorectal
cancer patients. The present studies reveal that the number of lymph nodes available for
molecular evaluation is an essential parameter that maximizes the prognostic value of occult
tumor burden analysis. They suggest that including >12 lymph nodes in occult tumor burden
Hyslop et al. Page 7
J Surg Oncol. Author manuscript; available in PMC 2013 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
analysis provides nearly complete resolution of risk classification in pN0 colorectal cancer
patients.
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Figure 1. Time to Recurrence in Patients with pN0 Colorectal Cancer Stratified by Occult
Tumor Burden Analysis
Time to recurrence in low (red line), intermediate (blue line) and high (yellow line) risk
categories established by occult tumor burden (p<0.001). Time to recurrence in the
uncategorized 282 pN0 patient cohort (black dashed line) ±95% confidence intervals (black
dotted line) is provided for comparison. Censored values reflect death from another cancer, a
non-cancer related death, death due to the cancer treatment, or loss of follow-up of
individual patients [25]. Table below Kaplan Meier plot summarize the number of patients
at risk as well as cumulative events for each outcome.
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Figure 2. Occult tumor burden and the number of analytic lymph nodes assessed by RT-qPCR
(A) Relationship between the number of lymph nodes harvested for histopathology and the
number analyzed to quantify occult tumor burden (R=0.49, p<0.001). (B) Differential
stratification of risk in patients with ≤12 or >12 lymph nodes evaluated by GUCY2C RT-
qPCR to quantify occult tumor burden (p<0.001).
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Figure 3.
Probability of risk classification associated with number of analytic lymph nodes evaluated
by RT-qPCR.
Hyslop et al. Page 13
J Surg Oncol. Author manuscript; available in PMC 2013 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Hyslop et al. Page 14
Table I
Patient Characteristics by Risk Group.
Overall Low Risk(n=170)
Moderate Risk
(n=88)
High Risk
(n=24) P†
Characteristic n %++ %++ %++
Race 0.007
 Black 23 47.8 26.1 26.1
 White 259 61.4 31.7 6.9
Age at Diagnosis 0.83
 <65 106 62.3 29.3 8.5
 ≥65 175 58.9 32.6 8.5
Sex 0.83
 Male 157 60.5 31.9 7.6
 Female 125 60.0 30.4 9.6
Location 0.59
 Colon 243 59.2 31.7 9.1
 Rectal 39 66.7 28.2 5.1
Differentiation 0.69
 Poor/unknown 45 60.0 33.3 6.7
 Moderate 217 59.0 31.8 9.2
 Well 20 75.0 20.0 5.0
T Stage 0.008
 T1/T2 117 66.7 30.8 2.5
 T3/T4 165 55.8 31.5 12.7
Lymphovascular Invasion 0.34
 No 224 61.2 29.4 9.4
 Yes 58 56.9 37.9 5.2
Treatment 0.40
 Surgery alone 218 60.6 2.1 7.3
 Surgery + chemotherapy 64 59.4 28.1 12.5
Nodes Harvested for Histopathology 0.003
 ≤12 59 55.0 45.0 0.0
 >12 223 62.2 27.0 10.8
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++
Row percentage.
†
P value from chi-square test of association.
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Table II
Patient Characteristics by Number of Lymph Nodes Harvested for Histopathology.
Overall ≤12 (n=59) >12 (n=223) p†
Characteristic n %‡ %‡
Age at Diagnosis 0.73
 <65 106 21.1 78.3
 ≥65 176 20.0 80.0
Sex 0.22
 Male 157 23.6 76.4
 Female 125 17.6 82.4
Location 0.23
 Colon 243 19.8 80.3
 Rectal 39 28.2 71.8
Differentiation 0.31
 Poor/unknown 45 28.9 71.1
 Moderate 217 19.8 80.2
 Well 20 15.0 85.0
T Stage 0.45
 T1/T2 117 23.1 76.9
 T3/T4 165 19.4 80.6
Lymphovascular Invasion 0.26
 No 224 22.3 77.7
 Yes 58 15.5 84.5
Treatment 0.57
 Surgery alone 218 20.2 79.8
 Surgery + chemotherapy 64 23.4 76.6
Race 0.66
 Black 23 17.4 82.6
 White 259 21.2 78.8
†
P value from chi-square test of association.
‡% of total for each category of characteristic.
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Table III
Multivariable Polytomous Logistic Regression Model.
Overall Adjusted Odds Ratio 95% CI p†
Characteristic n (AOR)
Race
 White 259 Referent ---
 Black (Moderate vs Low) 23 1.34 (0.21, 2.31) 0.30†
 Black (High vs Low) 4.05 (1.01, 16.67) 0.03†
T Stage
 T1/T2 117 Referent ---
 T3 (Moderate vs Low) 145 1.38 (0.86, 2.27) 0.09†
 T3 (High vs Low) 5.51 (2.15, 31.1) <0.001†
 T4 (Moderate vs Low) 20 2.12
 T4 (High vs Low) 3.41 (0.10, 37.13) 0.34
Analytic Nodes (continuous) 282
 Moderate vs Low
−0.05‡ (−0.22, −0.02)‡ <0.001
 High vs Low 0.08‡ (0.04, 0.12)‡ <0.001
†
P value from multivariable logistic regression model, based on 5,000 bootstrap samples.
‡Values are in original scale, and represent coefficient of smooth function, , not odds ratio.
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